½ÃÀ庸°í¼­
»óǰÄÚµå
1600610

ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå : ´Ü°èº°, À¯Çüº°, Á¦Ç°º°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Clinical Trial Supplies Market by Phase (Phase I, Phase II, Phase III), Type (Biologic Drugs, Medical Devices, Small-Molecules), Product, Therapeutic Area, End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀåÀÇ 2023³â ±Ô¸ð´Â 33¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 36¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.43%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 59¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå¿¡´Â ÀǾàǰ, ÀÇ·á±â±â, ±âŸ ½ÃÇè °ü·Ã Àç·á µî ÀÓ»ó½ÃÇè ¼öÇà¿¡ ÇÊ¿äÇÑ ¹°Ç°ÀÇ Á¦Á¶, Æ÷Àå, ¶óº§¸µ, À¯ÅëÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¼Ò¸ðǰÀÇ ÁÖ¿ä Çʿ伺Àº »õ·Î¿î Ä¡·á¹ýÀÌ È¯ÀÚ¿¡°Ô µµ´ÞÇϱâ Àü¿¡ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ Å×½ºÆ®¸¦ ÃËÁøÇÏ´Â ¿ªÇÒ¿¡ ÀÖ½À´Ï´Ù. Àû¿ë ¹üÀ§´Â Á¦¾à, »ý¸í°øÇÐ, ÀÇ·á±â±â ¹× ±âŸ »ý¸í°úÇÐ ºÐ¾ß¿¡ °ÉÃÄ ÀÖÀ¸¸ç, Á¦¾à ´ë±â¾÷, ¿¬±¸ ±â°ü, Çмú ±â°ü µî ÃÖÁ¾ »ç¿ëÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¸¸¼º Áúȯ Áõ°¡, »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀü, Ȱ¹ßÇÑ R&D ÅõÀÚ·Î ÀÎÇÑ ÀÓ»ó½ÃÇè Áõ°¡¸¦ µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó½ÃÇèÀÇ ¼¼°èÈ­·Î ÀÎÇØ È¿À²ÀûÀÎ °ø±Þ¸Á Àü·«ÀÌ ÇÊ¿äÇØÁö¸é¼­ ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ±â¼ú ÅëÇÕ°ú Äڷγª19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ÀÓ»ó½ÃÇèÀÇ Å»Áß¾ÓÈ­ ¹× °¡»óÈ­ µî ÃÖ±Ù µ¿ÇâÀº ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷µéÀº Åõ¸í¼ºÀ» À§ÇÑ ºí·ÏüÀÎ, ¹°·ù ÃÖÀûÈ­¸¦ À§ÇÑ AI¿Í °°Àº Çõ½ÅÀûÀÎ µðÁöÅÐ µµ±¸¿¡ ÅõÀÚÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ³ôÀº ºñ¿ë, °ø±Þ¸Á º¹À⼺ µîÀÇ ¹®Á¦´Â ¼ºÀåÀÇ Á¦¾àÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ±Øº¹Çϱâ À§Çؼ­´Â ±ÔÁ¦ Áؼö¿Í ºñ¿ë È¿À²¼º¿¡ Àü·«ÀûÀ¸·Î ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ÄݵåüÀÎ ¹°·ù, ÀûÀÀÁõ ½ÃÇè ¼³°è, ¸ÂÃã ÀÇ·á ºÐ¾ßÀÇ Çõ½ÅÀº ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­ÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. À̸¦ À§ÇØ ±â¾÷µéÀº ÷´Ü ÃßÀû ½Ã½ºÅÛ°ú °­·ÂÇÑ Å¬¶ó¿ìµå ±â¹Ý ¼Ö·ç¼ÇÀ» ¸ð»öÇÏ¿© °ø±Þ ¾ÈÀü¼ºÀ» ³ô¿©¾ß ÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ³ôÀº °æÀï°ú ºü¸¥ ±â¼ú ¹ßÀüÀÌ Æ¯Â¡À̸ç, ¹Îø¼º°ú Áö¼ÓÀûÀÎ Çõ½ÅÀÌ ¿ä±¸µÇ´Â ½ÃÀåÀÔ´Ï´Ù. Àü¹ÝÀûÀ¸·Î, ¼ºÀåÇϰíÀÚ ÇÏ´Â ±â¾÷Àº Á¾ÇÕÀûÀÎ ÄÄÇöóÀ̾𽺠Àü·«°ú ÷´Ü ¹°·ù ÇÁ·¹ÀÓ¿öÅ©¸¦ ÅëÇØ ÀÌ·¯ÇÑ °úÁ¦¸¦ ÇØ°áÇϰí, È¿À²¼º°ú ½Å·Ú¼ºÀ» ¾à¼ÓÇÏ´Â »õ·Î¿î ±â¼úÀ» µµÀÔÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¾ß¿¡ ÁßÁ¡À» µÎ¸é °æÀï·ÂÀ» À¯ÁöÇϸ鼭 ÁøÈ­ÇÏ´Â ÀÓ»ó½ÃÇèÀÇ ¿ä±¸¿¡ ´ëÀÀÇÏ°í ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 33¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 36¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 59¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 8.43%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è °¨¿°º´ ¹× ¸¸¼ºÁúȯÀÇ À¯Çà Áõ°¡
    • Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à¾÷°èÀÇ R&D ºñ¿ë Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀÓ»ó½ÃÇè ¿ëǰÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • ÀǾàǰ °³¹ßÀÇ Á߿伺°ú ȯÀÚ Áß½ÉÀÇ ÀÓ»ó½ÃÇèÀ¸·ÎÀÇ º¯È­
    • ´Ù¾çÇÑ ÀÓ»ó½ÃÇè ¿ëǰÀÇ Áö¼ÓÀûÀÎ ¹ßÀü
  • ½ÃÀå °úÁ¦
    • ÀÓ»ó½ÃÇè ¿ëǰ¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦

Portre's Five Forces ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå : ´Ü°èº°

  • ´Ü°è I
  • ´Ü°è II
  • ´Ü°è III
  • ´Ü°è IV

Á¦7Àå ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå : À¯Çüº°

  • »ý¹°ÇÐÀû Á¦Á¦
  • ÀÇ·á±â±â
  • ¼ÒºÐÀÚ

Á¦8Àå ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå : Á¦Ç°º°

  • º¸Á¶ ÀǾàǰ
  • ÀÎÅÍ·¢Æ¼ºê ¸®½ºÆù½º Å×Å©³î·¯Áö(IRT) ¼Ö·ç¼Ç
  • ½ÇÇè ¿ëǰ
    • ¿ø½ÉºÐ¸®±â
    • Çö¹Ì°æ
    • ÇÇÆê
    • ½Ã¾à
  • ÀÇ·á±â±â ¹× Áø´Ü
  • ¾à±¹ ¿ëǰ
    • Biohazard Bags
    • Compounding Aseptic Isolators
    • Sterilization Equipment
  • ¿¬±¸ ÀÚ·á
  • ¾ÈÀü Àåºñ

Á¦9Àå ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå : Ä¡·á ¿µ¿ªº°

  • ½ÉÀ庴ÇÐ
  • À¯Àü¼º Áúȯ
  • ¸é¿ªÇÐ
  • °¨¿°Áõ
  • ´ë»çÀå¾Ö
  • ½Å°æÇÐ
  • Á¾¾çÇÐ

Á¦10Àå ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • °è¾à¿¬±¸±â°ü
  • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÓ»ó½ÃÇè ¿ëǰ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Johnson & Johnson Services, Inc.
  • Bruker Corporation
  • Cardinal Health, Inc.
  • Rubicon Research Pvt. Ltd.
  • Sharp Services, LLC
  • Emsere B.V by Medicapital Holdco B.V.
  • Medline Industries, LP
  • Thermo Fisher Scientific Inc.
  • Novo Nordisk A/S
  • Evident Corporation by Olympus Corporation
  • KLIFO A/S
  • Merck KGaA
  • Almac Group Limited
  • Woodley Equipment Company Ltd.
  • Lonza Group Ltd.
  • Pfizer Inc.
  • Leica Microsystems GmbH by Danaher Corporation
  • Myonex, LLC
  • Becton, Dickinson and Company
  • Stryker Corporation
  • Promega Corporation
  • Nuvisan GmbH
  • Incyte Corporation
  • 3M Company
  • Recipharm AB
  • Charles River Laboratories, Inc.
  • Siemens Healthcare GmbH
  • IQVIA Inc.
  • Parexel International Corporation
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • HORIBA, Ltd.
  • ICON PLC
  • Bio-Rad Laboratories, Inc.
  • COREX LOGISTICS LIMITED
  • Perceptive Informatics LLC and its affiliates, d/b/a Calyx
  • Immudex ApS
  • Eppendorf SE
  • Abbott Laboratories
  • PerkinElmer Inc. by Revvity, Inc.
  • Fujifilm Group
  • Hitachi, Ltd.
  • Hipro Biotechnology Co., Ltd.
  • Labnet International
  • Baxter International, Inc.
  • B. Braun SE
  • llumina, Inc.
  • Sekisui Diagnostics Group
  • Smith & Nephew PLC
LSH

The Clinical Trial Supplies Market was valued at USD 3.35 billion in 2023, expected to reach USD 3.64 billion in 2024, and is projected to grow at a CAGR of 8.43%, to USD 5.92 billion by 2030.

The clinical trial supplies market encompasses the manufacturing, packaging, labeling, and distribution of supplies needed to conduct clinical trials, including drugs, medical devices, and other study-related materials. The primary necessity of these supplies lies in their role in facilitating rigorous testing to ensure safety and efficacy before new treatments reach patients. The application scope extends across pharmaceuticals, biotechnology, medical devices, and other life sciences sectors, targeting end-users such as pharmaceutical giants, research organizations, and academic institutions. Key factors driving market growth include increasing clinical trials propelled by rising chronic diseases, advancing biotechnology, and robust R&D investments. Moreover, the globalization of clinical trials necessitates efficient supply chain strategies, further propelling market expansion. Recent trends involving decentralized and virtual trials due to technological integration and the COVID-19 pandemic offer potential opportunities. Businesses can capitalize on these by investing in innovative digital tools, such as blockchain for transparency or AI for logistics optimization. However, challenges like stringent regulatory requirements, high costs, and supply chain complexities pose growth constraints. Navigating these demands a strategic focus on regulatory compliance and cost efficiency. Innovations in cold chain logistics, adaptive trial designs, and personalized medicine can further spurn growth. To do so, companies should explore advanced tracking systems or robust cloud-based solutions to enhance supply security. The market is characterized by high competition and rapid technological advancements, necessitating agility and continual innovation. Overall, businesses aspiring for growth need not only to address these challenges with comprehensive compliance strategies and advanced logistical frameworks but also to embrace emerging technologies that promise efficiency and reliability. Emphasizing these areas will position businesses to leverage opportunities, addressing the evolving needs of clinical trials while maintaining a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 3.35 billion
Estimated Year [2024] USD 3.64 billion
Forecast Year [2030] USD 5.92 billion
CAGR (%) 8.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Trial Supplies Market

The Clinical Trial Supplies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of infectious and chronic diseases worldwide
    • Rising research and development expenditure by pharmaceutical and biopharmaceutical industry
  • Market Restraints
    • High cost of clinical trial supplies
  • Market Opportunities
    • Emphasis on drug development and shift towards patient-centric clinical trials
    • Ongoing advancements in a diverse range of clinical trial supplies
  • Market Challenges
    • Stringent regulations for clinical trial supplies

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Trial Supplies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Trial Supplies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Trial Supplies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Trial Supplies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Trial Supplies Market

A detailed market share analysis in the Clinical Trial Supplies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Trial Supplies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Trial Supplies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Clinical Trial Supplies Market, highlighting leading vendors and their innovative profiles. These include Johnson & Johnson Services, Inc., Bruker Corporation, Cardinal Health, Inc., Rubicon Research Pvt. Ltd., Sharp Services, LLC, Emsere B.V by Medicapital Holdco B.V., Medline Industries, LP, Thermo Fisher Scientific Inc., Novo Nordisk A/S, Evident Corporation by Olympus Corporation, KLIFO A/S, Merck KGaA, Almac Group Limited, Woodley Equipment Company Ltd., Lonza Group Ltd., Pfizer Inc., Leica Microsystems GmbH by Danaher Corporation, Myonex, LLC, Becton, Dickinson and Company, Stryker Corporation, Promega Corporation, Nuvisan GmbH, Incyte Corporation, 3M Company, Recipharm AB, Charles River Laboratories, Inc., Siemens Healthcare GmbH, IQVIA Inc., Parexel International Corporation, F. Hoffmann-La Roche Ltd., Bayer AG, HORIBA, Ltd., ICON PLC, Bio-Rad Laboratories, Inc., COREX LOGISTICS LIMITED, Perceptive Informatics LLC and its affiliates, d/b/a Calyx, Immudex ApS, Eppendorf SE, Abbott Laboratories, PerkinElmer Inc. by Revvity, Inc., Fujifilm Group, Hitachi, Ltd., Hipro Biotechnology Co., Ltd., Labnet International, Baxter International, Inc., B. Braun SE, llumina, Inc., Sekisui Diagnostics Group, and Smith & Nephew PLC.

Market Segmentation & Coverage

This research report categorizes the Clinical Trial Supplies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Type, market is studied across Biologic Drugs, Medical Devices, and Small-Molecules.
  • Based on Product, market is studied across Auxiliary Medicinal Products, Interactive Response Technology (IRT) solutions, Lab Supplies, Medical Devices & Diagnostics, Pharmacy Supplies, Research Materials, and Safety Equipment. The Lab Supplies is further studied across Centrifuges, Microscopes, Pipettes, and Reagents. The Pharmacy Supplies is further studied across Biohazard Bags, Compounding Aseptic Isolators, and Sterilization Equipment.
  • Based on Therapeutic Area, market is studied across Cardiology, Genetic Diseases, Immunology, Infectious Diseases, Metabolic Disorders, Neurology, and Oncology.
  • Based on End User, market is studied across Contract Research Organisations and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious and chronic diseases worldwide
      • 5.1.1.2. Rising research and development expenditure by pharmaceutical and biopharmaceutical industry
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of clinical trial supplies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emphasis on drug development and shift towards patient-centric clinical trials
      • 5.1.3.2. Ongoing advancements in a diverse range of clinical trial supplies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for clinical trial supplies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Growing demand for clinical trial supplies for each phase for optimal decision-making regarding clinical trial
    • 5.2.2. Type: Surge in biologic drugs demand with breakthrough therapies for chronic ailments
    • 5.2.3. Product: Auxiliary medicinal products are vital elements of clinical trials, owing to their significance of assuring safety, and efficiency in the overall research operation
    • 5.2.4. Therapeutic Area: Rising burden of infectious diseases worldwide create a demand for clinical trial supplies
    • 5.2.5. End User: Growing use of clinical trial supplies in CROs due to rising outsourcing of R&D activities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clinical Trial Supplies Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. Clinical Trial Supplies Market, by Type

  • 7.1. Introduction
  • 7.2. Biologic Drugs
  • 7.3. Medical Devices
  • 7.4. Small-Molecules

8. Clinical Trial Supplies Market, by Product

  • 8.1. Introduction
  • 8.2. Auxiliary Medicinal Products
  • 8.3. Interactive Response Technology (IRT) solutions
  • 8.4. Lab Supplies
    • 8.4.1. Centrifuges
    • 8.4.2. Microscopes
    • 8.4.3. Pipettes
    • 8.4.4. Reagents
  • 8.5. Medical Devices & Diagnostics
  • 8.6. Pharmacy Supplies
    • 8.6.1. Biohazard Bags
    • 8.6.2. Compounding Aseptic Isolators
    • 8.6.3. Sterilization Equipment
  • 8.7. Research Materials
  • 8.8. Safety Equipment

9. Clinical Trial Supplies Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiology
  • 9.3. Genetic Diseases
  • 9.4. Immunology
  • 9.5. Infectious Diseases
  • 9.6. Metabolic Disorders
  • 9.7. Neurology
  • 9.8. Oncology

10. Clinical Trial Supplies Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research Organisations
  • 10.3. Pharmaceutical & Biotechnology Companies

11. Americas Clinical Trial Supplies Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Clinical Trial Supplies Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Clinical Trial Supplies Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Signal: UK Clinical Research Provider Ergomed Bought Out in USD 888 Million Deal
    • 14.3.2. Thermo Fisher Scientific Launches New Smart Refrigerator Series
    • 14.3.3. Loftware and Tenthpin Collaborate on Clinical Supply Labeling
    • 14.3.4. Sitero Acquires Clario's eClinical Technology Suite to Enhance Clinical Trial Delivery
    • 14.3.5. Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
    • 14.3.6. BD Launches New Robotic System to Automate Clinical Flow Cytometry
    • 14.3.7. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
    • 14.3.8. IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma
    • 14.3.9. Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
    • 14.3.10. Siemens Healthineers Launch Laboratory Equipment R&D Centre in Swords
    • 14.3.11. Experic Closes USD 14 Million Series B Financing
    • 14.3.12. Medline Invests Additional USD 500M in Medical Supply Inventory to Boost Product Availability

Companies Mentioned

  • 1. Johnson & Johnson Services, Inc.
  • 2. Bruker Corporation
  • 3. Cardinal Health, Inc.
  • 4. Rubicon Research Pvt. Ltd.
  • 5. Sharp Services, LLC
  • 6. Emsere B.V by Medicapital Holdco B.V.
  • 7. Medline Industries, LP
  • 8. Thermo Fisher Scientific Inc.
  • 9. Novo Nordisk A/S
  • 10. Evident Corporation by Olympus Corporation
  • 11. KLIFO A/S
  • 12. Merck KGaA
  • 13. Almac Group Limited
  • 14. Woodley Equipment Company Ltd.
  • 15. Lonza Group Ltd.
  • 16. Pfizer Inc.
  • 17. Leica Microsystems GmbH by Danaher Corporation
  • 18. Myonex, LLC
  • 19. Becton, Dickinson and Company
  • 20. Stryker Corporation
  • 21. Promega Corporation
  • 22. Nuvisan GmbH
  • 23. Incyte Corporation
  • 24. 3M Company
  • 25. Recipharm AB
  • 26. Charles River Laboratories, Inc.
  • 27. Siemens Healthcare GmbH
  • 28. IQVIA Inc.
  • 29. Parexel International Corporation
  • 30. F. Hoffmann-La Roche Ltd.
  • 31. Bayer AG
  • 32. HORIBA, Ltd.
  • 33. ICON PLC
  • 34. Bio-Rad Laboratories, Inc.
  • 35. COREX LOGISTICS LIMITED
  • 36. Perceptive Informatics LLC and its affiliates, d/b/a Calyx
  • 37. Immudex ApS
  • 38. Eppendorf SE
  • 39. Abbott Laboratories
  • 40. PerkinElmer Inc. by Revvity, Inc.
  • 41. Fujifilm Group
  • 42. Hitachi, Ltd.
  • 43. Hipro Biotechnology Co., Ltd.
  • 44. Labnet International
  • 45. Baxter International, Inc.
  • 46. B. Braun SE
  • 47. llumina, Inc.
  • 48. Sekisui Diagnostics Group
  • 49. Smith & Nephew PLC
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦